Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

ResMed (RMD) Stock Forecast & Price Target

ResMed logo
$275.36 -6.60 (-2.34%)
Closing price 08/28/2025 03:59 PM Eastern
Extended Trading
$275.50 +0.14 (+0.05%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings
Sell
1
Hold
3
Buy
12

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 3 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$274.83
-0.19% Downside
According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $274.83. The highest price target for RMD is $325.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -0.19% from the current price of $275.36.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

TypeCurrent Forecast
8/29/24 to 8/29/25		1 Month Ago
7/30/24 to 7/30/25		3 Months Ago
5/31/24 to 5/31/25		1 Year Ago
8/30/23 to 8/29/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$274.83$263.00$259.33$204.70
Forecasted Upside-0.19% Downside-5.18% Downside6.01% Upside-15.86% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-0.19% Downside15,720.89% Upside10.25% Upside
News Sentiment Rating
Positive News

See Recent RMD News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/1/2025William Blair
2 of 5 stars		 UpgradeStrong-Buy
8/1/2025UBS Group
3 of 5 stars		Laura Sutcliffe
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$285.00 ➝ $325.00+16.25%
8/1/2025Royal Bank Of Canada
3 of 5 stars		Craig Wong-Pan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$294.00 ➝ $300.00+7.31%
8/1/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jonathan Block
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetHold ➝ Hold$240.00 ➝ $270.00-3.42%
8/1/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$270.00 ➝ $290.00+3.73%
8/1/2025KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Brett Fishbin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$274.00 ➝ $298.00+9.49%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Adam Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetNeutral ➝ Neutral$248.00 ➝ $270.00-0.79%
5/20/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		David Bailey
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetOverweight ➝ Overweight$286.00+16.50%
4/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		David Low
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$286.00 ➝ $290.00+22.49%
3/5/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Mathieu Chevrier
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy
1/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingHold ➝ Hold
1/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Thillainathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$280.00 ➝ $283.00+18.39%
9/26/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$240.00 ➝ $270.00+11.12%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong-Buy
9/18/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingPeer Perform ➝ Underperform$180.00-28.25%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$240.00 ➝ $165.00+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:42 AM ET.


Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 27, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • Recent analyst upgrades have increased the price targets for ResMed Inc., with some analysts setting targets as high as $325.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $270, which reflects a favorable valuation compared to the average price target of approximately $274.83, suggesting potential for price appreciation.
  • ResMed Inc. has received multiple "buy" ratings from analysts, with a consensus rating of "Moderate Buy," indicating a generally positive outlook from market experts.
  • The company operates in the growing healthcare sector, focusing on innovative medical devices and cloud-based software applications, which positions it well for future growth.
  • Insider ownership is at 0.71%, which can be a positive indicator as it suggests that company executives have a vested interest in the company's performance.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • Despite the positive ratings, one analyst has issued a "sell" rating, which may indicate potential concerns about the company's future performance.
  • Recent reports show that some analysts have downgraded their ratings, such as Wall Street Zen lowering ResMed from a "buy" to a "hold," suggesting caution among some market participants.
  • The healthcare market can be highly competitive and subject to regulatory changes, which may impact ResMed Inc.'s operations and profitability.
  • While the stock has seen price increases, market volatility can lead to fluctuations that may affect short-term investment returns.
  • With a significant portion of the stock owned by institutional investors, individual investors may have less influence on company decisions and stock performance.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $274.83, with a high forecast of $325.00 and a low forecast of $180.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RMD shares.

According to analysts, ResMed's stock has a predicted downside of -0.19% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 2 upgrades by analysts.

ResMed has been rated by research analysts at KeyCorp, Mizuho, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and William Blair in the past 90 days.

Analysts like ResMed more than other "medical" companies. The consensus rating score for ResMed is 2.81 while the average consensus rating score for "medical" companies is 2.78. Learn more on how RMD compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:RMD) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel